Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$0.46 USD
+0.02 (4.36%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.39 -0.07 (-14.30%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADIL 0.46 +0.02(4.36%)
Will ADIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADIL
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ADIL
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's After-Market Session
Adial Pharmaceuticals (ADIL) Regains Nasdaq Compliance | ADIL Stock News
Adial Pharmaceuticals regains compliance with Nasdaq stockholders’ equity listing requirement